CANCER:

Neuroblastoma

Related cancers:

‹

CNS Tumor (309)

Brain Cancer (305)

Glioma (280)

Pituitary Gland Carcinoma (10)

Pituitary Gland Carcinoma (10)

Meningioma (5)

›

ALK positive ALK positive	Neuroblastoma Neuroblastoma	CAR-T immunotherapy Sensitive: D – Preclinical EACR 2021 - 3 weeks
No biomarker No biomarker	Neuroblastoma Neuroblastoma	dinutuximab beta Sensitive: A1 - Approval
No biomarker No biomarker	Neuroblastoma Neuroblastoma	doxorubicin hydrochloride Sensitive: A1 - Approval
No biomarker No biomarker	Neuroblastoma Neuroblastoma	melphalan Sensitive: A1 - Approval
No biomarker No biomarker	Neuroblastoma Neuroblastoma	dinutuximab Sensitive: A1 - Approval
No biomarker No biomarker	Neuroblastoma Neuroblastoma	cyclophosphamide oral Sensitive: A1 - Approval
No biomarker No biomarker	Neuroblastoma Neuroblastoma	naxitamab Sensitive: A1 - Approval
ALK positive ALK positive	Neuroblastoma Neuroblastoma	crizotinib Sensitive: C1 - Off-label
ALK R1275Q ALK R1275Q	Neuroblastoma Neuroblastoma	crizotinib Sensitive: C3 – Early Trials
ATRX mutation ATRX mutation	Neuroblastoma Neuroblastoma	AZD1775 Sensitive: C3 – Early Trials
ALK rearrangement + ALK R1275Q + TP53 mutation ALK rearrangement + ALK R1275Q + TP53 mutation	Neuroblastoma Neuroblastoma	crizotinib Resistant: C4 – Case Studies
PGBD5 overexpression PGBD5 overexpression	Neuroblastoma Neuroblastoma	cisplatin Sensitive: D – Preclinical
PGBD5 overexpression PGBD5 overexpression	Neuroblastoma Neuroblastoma	AZD6738 Sensitive: D – Preclinical
PGBD5 underexpression PGBD5 underexpression	Neuroblastoma Neuroblastoma	AZD6738 Sensitive: D – Preclinical
ALK R1275Q ALK R1275Q	Neuroblastoma Neuroblastoma	TAE-684 Resistant: D – Preclinical
MYCN amplification MYCN amplification	Neuroblastoma Neuroblastoma	GSK2816126 + MTX110 Sensitive: D – Preclinical
MYCN amplification MYCN amplification	Neuroblastoma Neuroblastoma	OTX015 Sensitive: D – Preclinical
MYCN amplification MYCN amplification	Neuroblastoma Neuroblastoma	JQ-1 + MTX110 Sensitive: D – Preclinical
MYCN amplification MYCN amplification	Neuroblastoma Neuroblastoma	brigatinib Resistant: D – Preclinical
MYCN amplification MYCN amplification	Neuroblastoma Neuroblastoma	crizotinib Resistant: D – Preclinical
ALK F1174L ALK F1174L	Neuroblastoma Neuroblastoma	crizotinib Resistant: D – Preclinical
ALK F1174L ALK F1174L	Neuroblastoma Neuroblastoma	AZD3463 Sensitive: D – Preclinical
ALK F1174L ALK F1174L	Neuroblastoma Neuroblastoma	alectinib Sensitive: D – Preclinical
ALK amplification ALK amplification	Neuroblastoma Neuroblastoma	alectinib Sensitive: D – Preclinical
ALK F1245C ALK F1245C	Neuroblastoma Neuroblastoma	lorlatinib Sensitive: D – Preclinical
ALK F1174C ALK F1174C	Neuroblastoma Neuroblastoma	lorlatinib Sensitive: D – Preclinical
ALK F1174L ALK F1174L	Neuroblastoma Neuroblastoma	TAE-684 Sensitive: D – Preclinical
MYCN amplification + ALK rearrangement MYCN amplification + ALK rearrangement	Neuroblastoma Neuroblastoma	brigatinib Sensitive: D – Preclinical
MYCN amplification + ALK F1174V MYCN amplification + ALK F1174V	Neuroblastoma Neuroblastoma	brigatinib Sensitive: D – Preclinical
MYCN amplification + ALK F1174V MYCN amplification + ALK F1174V	Neuroblastoma Neuroblastoma	crizotinib Sensitive: D – Preclinical
NF1 underexpression NF1 underexpression	Neuroblastoma Neuroblastoma	binimetinib Sensitive: D – Preclinical
MYCN amplification + ALK F1174L MYCN amplification + ALK F1174L	Neuroblastoma Neuroblastoma	lorlatinib Sensitive: D – Preclinical
ALK D1091N ALK D1091N	Neuroblastoma Neuroblastoma	AZD3463 Sensitive: D – Preclinical
MYCN amplification + ALK rearrangement MYCN amplification + ALK rearrangement	Neuroblastoma Neuroblastoma	crizotinib Sensitive: D – Preclinical
MYCN amplification + ALK R1275Q MYCN amplification + ALK R1275Q	Neuroblastoma Neuroblastoma	lorlatinib Sensitive: D – Preclinical
ETV6-NTRK3 fusion ETV6-NTRK3 fusion	Neuroblastoma Neuroblastoma	TPX-0005 Sensitive: D – Preclinical
CD276 expression CD276 expression	Neuroblastoma Neuroblastoma	B7H3-targeted CAR-T immunotherapy Sensitive: D – Preclinical
TERT rearrangement TERT rearrangement	Neuroblastoma Neuroblastoma	OTX015 Sensitive: D – Preclinical

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

Neuroblastoma

Associations(38)

Associations
(38)